NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Diabeloop

Diabeloop

Private
GrenobleHealthcare & Life Scienceshttps://www.diabeloop.com/

Last Round

Series C

Extension

Mar 4, 2024

Total Funding Raised

$143.57M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Diabeloop is a medical technology company that develops artificial intelligence-based solutions to automate and personalize the treatment of diabetes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Health IoT

Business Model

B2B2C

Customer Profile

Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

automated insulin deliveryAIDartificial pancreascontinuous glucose monitorCGMtype 1 diabetesinsulin pumpmedical AIglycemic controldigital healthinteroperable softwarediabetes managementhealth IoTmedical device software

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Diabeloop Comparables

Compare Diabeloop with similar companies based on industry and business-model similarity.

Diabeloop comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CamDiab Ltd
89%
Beta Bionics
82%
Inreda Diabetic B.V.
81%

Diabeloop Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionMar 4, 2024
Series CJun 2, 2022
DebtJun 2, 2022
GrantMar 31, 2021
Series BDec 2, 2019
Grant
Nov 1, 2018

Key People

Founding team and executive leadership

François MICELI

Chairman Chief Executive Officer

Executive Team

Diabeloop Investors

Notable investors and investment history

Diabeloop investors
InvestorRounds
Odyssée VentureSeries B, Series C
European Innovation Council FundGrant
KreaxiSeries B, Series A, Series C
Sofimac InnovationSeries B
InnovacomSeries C
Supernova InvestSeries B, Series A, Series C
Air Liquide Venture CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 10, 2026

    Equipped over 10,000 people since 2021 launch.

  • Mar 9, 2026

    Attending the Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference.

Diabeloop Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Diabeloop Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Diabeloop's valuation, stock price, and market status.

Firmographic Details

HeadquartersGrenoble
Employee Range80
Year Founded2015
Last FundingMar 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.